Epitopea Announces License and Research Collaboration Agreement with MSD to Identify Cryptigen™ Tumor-Specific Antigens
Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, ...
FierceBiotech4d
Merck pens $300M-per-product collab with Epitopea to locate 'hidden' tumor antigens
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...
Pharm Exec4d
Epitopea Strikes Research Collaboration with Merck, Appoints Klaus Edvardsen as Chief Medical Officer
Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.
Business Insider4d
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify Cryptigen™ Tumor-Specific Antigens
MONTREAL and CAMBRIDGE, United Kingdom, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies ...
PharmiWeb4d
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens
Montreal, Quebec and Cambridge, UK February 19, 2025: Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, announces a license ...
The Pharma Letter5d
Merck & Co sees enough in Epitopea to sign deal
Epitopea, an Anglo-Canadian company developing accessible, off-the-shelf RNA-based immunotherapies for cancer, has announced a license and research collaboration deal with US pharma giant Merck & Co ...